Skip to Content

Bimekizumab – Blocking of Both IL-17A and IL-17F: What Does It Mean for Us Dermatologists and Our patients?

The European Union’s approval of bimekizumab (BIMZELX®) for the treatment of moderate-to-severe plaque psoriasis on August 31st, 2021, has finally been cleared by Norway on November 22nd, 2022, making it the last country in Scandinavia to approve the product.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top